Updated guidance on promotional labeling for biosimilars and interchangeables emphasizes a similar approach

BY RACHEL COE, MSC

The FDA issued a revised draft guidance on the development of promotional labeling for biosimilars, reference products, and—newly—interchangeable products. But the guidance offers little in the way of advice for sponsors of interchangeable products, except to say that companies shouldn’t imply that their products are better than the competition.

Fill out the form to read the full article.